Indication intelligence, analysis and sector perception

Kite Pharma (KITE) and GE Global Research collaborate to automate manufacturing of Engineered T Cell Therapies

December 3, 2015 8:27am

Under the terms of the agreement, Kite and GE Global Research will each contribute resources and relevant expertise to the partnership. Further terms of the agreement are not being disclosed.

KITE and GE Global Research (GE) have formed a strategic research collaboration to develop a next-generation, functionally integrated and automated manufacturing system for engineered T cell therapy.

The Bottom Line; This collaboration brings capabilities from each company, including Kite's scientific leadership in T cell biology and manufacturing and GE Global Research's deep expertise in the design and development of innovative manufacturing applications.

KITE closed at $72.86 – DOWN -$3.19 ... on the news, it’s probably a wash, each contribute to lower costs by spending money now - HOLD.

But, it also says … other contract manufacturing companies were excluded - guess who?

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

32 min ago
RegMed Investors (RMi) Closing Bell: I told you so

9 hours 20 min ago
RegMed Investors’ (RMi) pre-open: It’s “make” a buck day!

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.